ArticleJournal of immunology (Baltimore, Md. : 1950)2014
Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Exploring Siglecs: Potential Modulators of Immune Cells in Food Allergy and Therapeutic Applications.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.The Journal of biological chemistry · 2024Article
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments.Nanomedicine : nanotechnology, biology, and medicine · 2023Review
- Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer.Frontiers in cell and developmental biology · 2022Article
- Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Glyceraldehyde-3-phosphate Dehydrogenase Common Peptides ofVaccines · 2021Article
- Generation of Liposomes to Study the Effect ofInternational journal of molecular sciences · 2021Article
- Recent Advances in the Chemical Biology ofMolecules (Basel, Switzerland) · 2021Review
- Glycan-binding profile of DC-like cells.Glycoconjugate journal · 2020Article
- Unbiased Identification of Angiogenin as an Endogenous Antimicrobial Protein With Activity Against VirulentFrontiers in microbiology · 2020Article
- Glycan recognition by human blood mononuclear cells with an emphasis on dendritic cells.Glycoconjugate journal · 2018Article
- Cell-based glycan arrays for probing glycan-glycan binding protein interactions.Nature communications · 2018Article
- Induction ofFrontiers in immunology · 2018Article
- The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Frontiers in immunology · 2018Review
- The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery.Frontiers in immunology · 2018Review
- Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- From Immunologically Archaic to Neoteric Glycovaccines.Vaccines · 2017Review
- Carbohydrates as T-cell antigens with implications in health and disease.Glycobiology · 2016Review
- Dectin-2 Recognizes Mannosylated O-antigens of Human Opportunistic Pathogens and Augments Lipopolysaccharide Activation of Myeloid Cells.The Journal of biological chemistry · 2016Article
- Donor-unrestricted T cells in the human CD1 system.Immunogenetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Lipids from mycobacteria can be presented to human T cells by group 1 CD1 Ag-presenting molecules (CD1a, CD1b, and CD1c). Group 1 CD1-restricted T cells are activated by lipid Ags presented by myeloid dendritic cells (DCs), after which they generate antibacterial effector functions, including IFN-γ secretion and cytolysis. Thus, mycobacterial lipids are being investigated as components of novel vaccines for mycobacterial infections. In this study we show that the mycobacterial lipid Ag C80 glucose-6-monomycolate can be delivered to human CD1b(+) DCs via targeted liposomal nanoparticles, leading to robust group 1 CD1-restricted activation of T cells. Targeting was achieved by decorating the liposomes with a high-affinity glycan ligand of sialic acid-binding Ig-like lectin (Siglec)-7, a siglec receptor expressed on DCs that mediates rapid endocytosis and transport of its cargo to lysosomes. An Ab to Siglec-7 completely blocked the binding of targeted liposomes to human monocyte-derived DCs (Mo-DCs), demonstrating their targeting specificity. Mo-DCs pulsed with targeted liposomes containing C80 glucose-6-monomycolate more potently activated a CD1b-restricted T cell line relative to Mo-DCs pulsed with free lipid Ag or antigenic liposomes without Siglec-7 ligand. These data suggest that the endocytic function of Siglec-7 can be exploited to deliver glycolipid Ags to their target cell and increase the efficiency of display to T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.